Park Vale Capital

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Dearman Ltd. specializes in clean cold and power technologies that utilize liquid air-powered engines. The company's primary innovation is the Dearman engine, a piston engine that operates on the expansion of liquid nitrogen or liquid air, providing zero-emission power and cooling solutions. This technology is applied in various sectors, including refrigerated transport for food and medicine, backup power and cooling for buildings, and urban vehicles such as city buses. Founded in 2011 and headquartered in London, Dearman aims to deliver significant reductions in operating costs, fuel consumption, and emissions through its proprietary technologies. The company is recognized for its commitment to innovation and engineering excellence, striving to contribute to a cleaner and more sustainable environment.

Causemo Inc. is a software as a service (SaaS) company that specializes in fundraising and donor segmentation solutions for nonprofit organizations. Founded in 2013 and based in Framingham, Massachusetts, Causemo offers a product called Causemo Insights, which leverages data science to enhance fundraising efforts. This platform enables organizations to better understand their donors by analyzing their preferences, interests, and preferred giving channels, thereby facilitating more effective fundraising strategies. Causemo operates as a subsidiary of The Pursuant Group, Inc.